Page last updated: 2024-11-12
secretin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 16129665 |
| SCHEMBL ID | 677502 |
| MeSH ID | M0019589 |
Synonyms (27)
| Synonym |
|---|
| secreflow |
| secretin (porcine), 15-l-glutamic acid-16-glycine- |
| secretinum [inn-latin] |
| secretin-ferring |
| secretine [inn-french] |
| l-histidyl-l-seryl-l-alpha-aspartylglycyl-l-threonyl-l-phenylalanyl-l-threonyl-l-seryl-l-alpha-glutamyl-l-leucyl-l-seryl-l-arginyl-l-leucyl-l-arginyl-l-alpha-aspartyl-l-seryl-l-alanyl-l-arginyl-l-leucyl-l-glutaminyl-l-arginyl-l-leucyl-l-leucyl-l-glutaminy |
| secretina [inn-spanish] |
| secretolin |
| l-histidyl-l-seryl-l-alpha-aspartylglycyl-l-threonyl-l-phenylalanyl-l-threonyl-l-seryl-l-alpha-glutamyl-l-leucyl-l-seryl-l-arginyl-l-leucyl-l-arginyl-l-alpha-glutamylglycyl-l-alanyl-l-arginyl-l-leucyl-l-glutaminyl-l-arginyl-l-leucyl-l-leucyl-l-glutaminylg |
| einecs 215-733-3 |
| secretin-kabi |
| secrepan |
| secretinum |
| unii-88c55n56uu |
| secretin [usan:inn:ban:dcf:jan] |
| secretina |
| secretine |
| 88c55n56uu , |
| gtpl3643 |
| gtpl1155 |
| 1393-25-5 |
| vitrum |
| secretin synthetic human |
| AKOS015896025 |
| SCHEMBL677502 |
| Q27088772 |
| secretin, human |
Research Excerpts
Overview
Secretin is a 27 amino acid peptide. It stimulates the secretion of bicarbonate, enzymes and potassium ion from the pancreas.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Secretin is a 27 amino acid peptide which stimulates the secretion of bicarbonate, enzymes and potassium ion from the pancreas. " | ( Molecular cloning and expression of a cDNA encoding the secretin receptor. Ishihara, T; Kaziro, Y; Nagata, S; Nakamura, S; Takahashi, K; Takahashi, T, 1991) | 1.97 |
| "Secretin is a gastrointestinal hormone responsible for the regulation of bicarbonate, potassium ion and enzyme secretion from the pancreas. " | ( Molecular cloning and functional characterization of a human secretin receptor. Chow, BK, 1995) | 1.98 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (13)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1346454 | Human VPAC1 receptor (VIP and PACAP receptors) | 1997 | Peptides, , Volume: 18, Issue:10 | Development of high affinity selective VIP1 receptor agonists. |
| AID1346434 | Rat VPAC1 receptor (VIP and PACAP receptors) | 1998 | Annals of the New York Academy of Sciences, Dec-11, Volume: 865 | Analogues of VIP, helodermin, and PACAP discriminate between rat and human VIP1 and VIP2 receptors. |
| AID1346433 | Human VPAC2 receptor (VIP and PACAP receptors) | 1997 | Peptides, , Volume: 18, Issue:10 | Development of high affinity selective VIP1 receptor agonists. |
| AID1346454 | Human VPAC1 receptor (VIP and PACAP receptors) | 1998 | Annals of the New York Academy of Sciences, Dec-11, Volume: 865 | Analogues of VIP, helodermin, and PACAP discriminate between rat and human VIP1 and VIP2 receptors. |
| AID1346435 | Rat PAC1 receptor (VIP and PACAP receptors) | 1997 | Peptides, , Volume: 18, Issue:10 | Development of high affinity selective VIP1 receptor agonists. |
| AID1346433 | Human VPAC2 receptor (VIP and PACAP receptors) | 1998 | Annals of the New York Academy of Sciences, Dec-11, Volume: 865 | Analogues of VIP, helodermin, and PACAP discriminate between rat and human VIP1 and VIP2 receptors. |
| AID1346434 | Rat VPAC1 receptor (VIP and PACAP receptors) | 1997 | Peptides, , Volume: 18, Issue:10 | Development of high affinity selective VIP1 receptor agonists. |
| AID1346470 | Rat VPAC2 receptor (VIP and PACAP receptors) | 1997 | Peptides, , Volume: 18, Issue:10 | Development of high affinity selective VIP1 receptor agonists. |
| AID1345934 | Rat secretin receptor (Glucagon receptor family) | 1991 | The EMBO journal, Jul, Volume: 10, Issue:7 | Molecular cloning and expression of a cDNA encoding the secretin receptor. |
| AID1346454 | Human VPAC1 receptor (VIP and PACAP receptors) | 1996 | European journal of pharmacology, Apr-29, Volume: 302, Issue:1-3 | Stable expression of the recombinant human VIP1 receptor in clonal Chinese hamster ovary cells: pharmacological, functional and molecular properties. |
| AID1346470 | Rat VPAC2 receptor (VIP and PACAP receptors) | 1998 | Annals of the New York Academy of Sciences, Dec-11, Volume: 865 | Analogues of VIP, helodermin, and PACAP discriminate between rat and human VIP1 and VIP2 receptors. |
| AID1345934 | Rat secretin receptor (Glucagon receptor family) | 1997 | Peptides, , Volume: 18, Issue:10 | Development of high affinity selective VIP1 receptor agonists. |
| AID1345990 | Human secretin receptor (Glucagon receptor family) | 1995 | Biochemical and biophysical research communications, Jul-06, Volume: 212, Issue:1 | Molecular cloning and functional characterization of a human secretin receptor. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 79.43
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (79.43) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Clinical Trials (33)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomised, Double Blind Cross-over Study of Serial MRCP Following Morphine-neostigmine and Secretin Provocation in Healthy Volunteers [NCT01134848] | Phase 4 | 10 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| MRCP With Secretin Stimulation for the Evaluation of Pancreatic Endocrine and Exocrine Function Following Surgical Resection for Pancreatic Adenocarcinoma [NCT01094535] | 0 participants (Actual) | Interventional | 2007-09-30 | Withdrawn(stopped due to Poor enrollment) | |||
| A Phase II Study to Establish the Efficacy of Synthetic Human SecretiN in Human Acute Pancreatitis (SNAP) Study [NCT03686618] | Phase 2 | 40 participants (Anticipated) | Interventional | 2018-10-01 | Recruiting | ||
| Effect of Secretin on Gastric Accommodation, Emptying and Post-nutrient Challenge Symptoms in Functional Dyspepsia and Healthy Subjects [NCT03617861] | Phase 1/Phase 2 | 20 participants (Actual) | Interventional | 2018-11-07 | Completed | ||
| Evaluation of Efficiency of Secretin-Assisted Computed Tomography Scan and Secretin-Assisted Magnetic Resonance Imaging in Improving Pancreatic Enhancement and Tumor Conspicuity: Prospective Study [NCT01371240] | Early Phase 1 | 0 participants (Actual) | Interventional | 2011-06-30 | Withdrawn(stopped due to Study never started) | ||
| Comparison of Secretin Enhanced MRCP to Endoscopic Pancreatic Function Testing in Diagnosing Exocrine Insufficiency in Patients Who Have Undergone Pancreas Cancer Resection [NCT01094600] | 0 participants (Actual) | Interventional | 2012-06-30 | Withdrawn | |||
| Secretin Increases Glucose Uptake in Human Brown Adipose Tissue and Induces Satiation. [NCT03290846] | Phase 2/Phase 3 | 23 participants (Actual) | Interventional | 2016-08-02 | Completed | ||
| Study to Assess Pancreatic Blood Flow at Rest and During Stimulation Using Magnetic Resonance Imaging (fMRI) in Patients With Chronic Pancreatitis [NCT02458118] | Phase 1/Phase 2 | 15 participants (Anticipated) | Interventional | 2012-06-30 | Recruiting | ||
| Aspiration of Duodenopancreatic Juice After Secretin Stimulation (ADPJ-secr-) vs Endoscopic Aspiration (EUS-FNA) for Molecular Analysis of Intraductal Papillary Mucinous Intraductal Neoplasia (IPMN). [NCT05914077] | Phase 3 | 140 participants (Anticipated) | Interventional | 2023-09-13 | Recruiting | ||
| Optical and Biochemical Biomarkers in Early Pancreatic Cancer Significance: A Prospective Study [NCT03404661] | 346 participants (Actual) | Observational | 2018-01-11 | Completed | |||
| Magnetic Resonance Cholangiopancreatography (MRCP): A Reliable, Non Invasive Method for Staging Chronic Pancreatitis From Minimal Change Disease to the Advanced Stages in Pediatrics [NCT02869893] | 57 participants (Actual) | Interventional | 2016-08-10 | Completed | |||
| Imaging Biomarkers of Pancreatic Function and Disease [NCT05659147] | Phase 4 | 195 participants (Anticipated) | Interventional | 2023-01-18 | Enrolling by invitation | ||
| RG1068 (Synthetic Human Secretin) Enhanced Multidetector CT Pancreatography: Evaluation of the Pancreatic Duct in Patients With Known or Suspected Chronic Pancreatitis [NCT00620919] | Phase 1 | 0 participants (Actual) | Interventional | 2008-02-29 | Terminated(stopped due to Poor patient enrollment due to logistical issues.) | ||
| The Cancer of the Pancreas Screening-5 CAPS5)Study [NCT02000089] | Phase 3 | 7,000 participants (Anticipated) | Interventional | 2014-01-06 | Recruiting | ||
| Intraductal Secretin Stimulation Test: What Is the Proper Collection Time? [NCT03263481] | 8 participants (Actual) | Interventional | 2017-09-01 | Completed | |||
| Phase III Study to Demonstrate the Efficacy and Safety of RG1068 (Synthetic Human Secretin)- Enhanced Magnetic Resonance Cholangiopancreatography (MRCP) in the Evaluation of Subjects With a History of Acute or Acute Recurrent Pancreatitis [NCT00660335] | Phase 3 | 258 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| The Role of Secretin on the Energy Homeostasis [NCT04613700] | 25 participants (Actual) | Interventional | 2020-03-01 | Completed | |||
| MRI With Secretin Enhancement to Increase Conspicuity of Pancreatic Cancer [NCT01094626] | 0 participants (Actual) | Interventional | 2010-04-30 | Withdrawn(stopped due to Pharmaceutical company did not decide to renew contract) | |||
| An Open-Label, Dose Escalation, Pilot Study to Assess the Safety and Efficacy of Subcutaneous RG1068 (Synthetic Human Secretin) in Patients With Obsessive Compulsive Disorder (OCD) [NCT00216294] | Phase 2 | 16 participants | Interventional | 2005-02-28 | Completed | ||
| Recurrent Abdominal Pain and Exocrine Pancreatic Insufficiency [NCT04231279] | Phase 3 | 800 participants (Anticipated) | Interventional | 2020-01-31 | Not yet recruiting | ||
| RG1068 (Synthetic Human Secretin) Enhanced MRCP for Morphological Evaluation of the Pancreatic Duct in the Pediatric Population [NCT00621283] | Phase 1 | 0 participants (Actual) | Interventional | 2008-02-29 | Terminated(stopped due to Poor patient enrollment due to logistical issues) | ||
| RG1068 (Synthetic Human Secretin) Enhanced MRCP for Morphological Evaluation of the Known or Suspected Intraductal Papillary Mucinous Neoplasms of the Pancreas [NCT00621556] | Phase 1 | 2 participants (Actual) | Interventional | 2008-02-29 | Terminated(stopped due to Poor patient enrollment due to logistical issues) | ||
| Screening for Early Pancreatic Neoplasia [NCT00438906] | 200 participants (Actual) | Observational | 2006-12-31 | Completed | |||
| Secretin Infusion for Pain Due to Chronic Pancreatitis [NCT01265875] | Phase 1/Phase 2 | 12 participants (Actual) | Interventional | 2010-12-31 | Completed | ||
| Evidence Based Management of Acute Biliary Pancreatitis [NCT04615702] | 30 participants (Actual) | Observational [Patient Registry] | 2017-05-15 | Completed | |||
| A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Efficacy, Safety and Tolerability of RG1068 (Synthetic Human Secretin) in Children With Autism [NCT00036244] | Phase 3 | 0 participants | Interventional | 2002-04-30 | Completed | ||
| Multisite Controlled Secretin Trial in Autism [NCT00065962] | Phase 3 | 85 participants | Interventional | 1999-06-30 | Completed | ||
| A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Efficacy, Safety and Tolerability of RG1068 (Synthetic Human Secretin) in Children With Autism and Gastrointestinal Dysfunction [NCT00036231] | Phase 3 | 0 participants | Interventional | 2002-04-30 | Terminated | ||
| Effects of RG1068 (Secretin) on Information Processing in Schizophrenia [NCT00235274] | Phase 2 | 30 participants | Interventional | 2005-11-30 | Completed | ||
| The Use of Non-invasive MRI to Quantify the Effect of Secretin on Pancreatic Blood Flow and Perfusion in Healthy Volunteers [NCT01452217] | Phase 1 | 12 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
| Secretin Infusion to Prevent Pancreatic Leaks Following Pancreatic Resection [NCT02160808] | Phase 2/Phase 3 | 170 participants (Actual) | Interventional | 2014-05-31 | Completed | ||
| Secretin-Stimulated MRCP as an Early Screening Modality for Pancreatic Ductal Abnormalities in Patients at High Risk for Pancreatic Adenocarcinoma: A Pilot Study [NCT01094561] | 23 participants (Actual) | Interventional | 2006-07-31 | Completed | |||
| Pilot Study Using Secretin and Iodinated Intravenous Contrast and 64-Channel CT in Patients at High Risk for Pancreatic Adenocarcinoma [NCT00587132] | Phase 1/Phase 2 | 4 participants (Actual) | Interventional | 2006-11-30 | Terminated(stopped due to Lack of funding) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||